Journal of the Korean Chemical Society (대한화학회지)

Korean Chemical Society (대한화학회)
권호 표지

Synthesis of 1-(4-Thio-${\alpha},{\beta}$-D-ribofuranosyl)-5-halogenouracils (II). 5-Fluoro-4'-thiouridine and 5-Chloro-4'-thio-uridine

5-할로겐 치환된 Uracil의 4-Thiosugar Nucleosides의 합성에 관한 연구 (제2보). 5-Fluoro-4'-thiouridine과 5-Chloro-4'-thiouridine의 합성

  • Jack C Kim (Department of Chemistry, College of Liberal Arts Science Busan National University) ;
  • Won-Jei Cho (Department of Chemistry, College of Liberal Arts Science Busan National University) ;
  • Miroslay Bobek (Department of Experimental Therapeutics) ;
  • Roy L. Whistler (Department of Biochemistry)
  • Published : 1975.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

The syntheses of anomeric mixtures of 1-(4-thio-${\alpha},{\beta}$-D-ribofuranosyl)-5-fluoro-and 5-chlorouracils from their corresponding bis(trimethylsilyl) derivatives of 5-halogenouracils and 2,3,5-tri-O-acetyl-4-thio-${\alpha},{\beta}$-D-ribofuranosyl chloride are described. Preliminary biochemical studies showed that in leukemia 1210 cells and Streptococcus faecium, the ${\beta}$-anomeric 5-chloro-4'-thionucleoside is not greatly different from the corresponding 4'-oxygen analog. However, the 5-fluoro-4'-thionucleoside showed a growth inhibitory effect more than that of the oxygen counterpart. The potential chemotherapeutic use of the analog is to warrant further study.

Unusual pyrimidine nucleoside인 5-fluoro-4'-thiouridine과 5-Chloro-4'-thiouridine을 5-fluoro-와 5-chlorouracil의 2,4-bis(trimethylsilyl) 유도체들을 만든후, 축합반응하여 합성하였다. Leukemia 1210 cell과 Streptococcus faecium에 대한 기초 생물화학적인 예비시험에 의하면 5-fluoro-4'-thiouridine은 5-fluorouridine보다 억제효과가 월등하여 항암제로서의 전망여하는 앞으로의 임상 화학적인 결과로 구명될것 이라고 예상된다.

Keywords

References

  1. Progr. Chem. and Chem. Ind.(Korea) v.14 J. C. Kim
  2. J. Korean Chem. Soc. v.19 J. C. Kim(et al.)
  3. Carbohydrate Res. v.31 J. C. Kim;R. L. Whistler
  4. J. Org. Chem. v.27 E. R. Reist;W. E. Dick;A. Benz;L. Goodman;B. R. Baker;W. W. Lee
  5. J. Med. Chem. v.13 T. A. Khwaja;C. Heidleberger
  6. Adv. Heterocyclic Chem. v.8 J. Pliml;M. Prystas
  7. J. Org. Chem. v.33 H. Iwamma;T. Flashiume
  8. J. Org. Chem. v.29 R. L. Whistler;T. R. Ingle;R. H. Rowell;B. Urbas
  9. J. Org. Chem. v.30 N. Yamaoka;K. Aso;K. Matsuda
  10. Netherlands Patent Application, 6,610,360 F. Hoffman-La Loche
  11. J. Org. Chem. v.31 B. Urbas;R. L. Whistler
  12. Tetrahedron v.25 P. Nuhn;A. Zschuwke;D. Heller;G. Wagner
  13. J. Med. Chem. v.15 S. Nesnow;A. Mian;T. Oki;D. Dexter;C. Heidelberger
  14. J. Org. Chem. v.31 E. Walton;F. Holly;G. Boxer;R. Nutt
  15. J. Amer. Chem. Soc. v.90 R.J. Cushley;I. Wempen;J. J. Fox
  16. Tetrahedron Lett. T. L. V. Ulbricht;T. R. Emerson;R. J. Swan
  17. Cancer Res. J. C. Kim(et al.)
  18. J. Amer. Chem. Soc. v.86 E. J. Reist;D. E. Gueffroy;L. Goodman